Literature DB >> 15100558

A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP).

Graham J Emslie1, Carroll W Hughes, M Lynn Crismon, Molly Lopez, Steve Pliszka, Marcia G Toprac, Christine Boemer.   

Abstract

OBJECTIVE: To evaluate the feasibility and impact on clinical response and function associated with the use of an algorithm-driven disease management program (ALGO) for children and adolescents treated for depression with or without attention-deficit/hyperactivity disorder (ADHD) in community mental health centers.
METHOD: Interventions included (1). medication algorithms, (2). clinical and technical support for the physician, (3). uniform chart documentation of outcomes, and (4). a patient/family psychoeducation program. Children eligible for entry into the study were referred to the child psychiatrist for initiation or change in medicine. Outcomes of treatment with the ALGO for up to 4 months are presented. Measures of change included clinical symptoms, functioning, and global improvement (Clinical Global Impression Scale). A historical chart cohort from the same clinics was used as a quasi-control.
RESULTS: Thirty-nine individuals (depression = 24; comorbid depression with ADHD = 15) were enrolled for treatment with ALGO. One hundred fourteen children were in the control cohort (74 depressed, 40 comorbid). For the ALGO groups, Children's Depression Rating Scale-Revised depression severity scores decreased from 48.2 to 32.5 and Child Adolescent Functioning Assessment Scale function scores improved from 70.3 to 40.9 (all p < or =.0005). Clinical Global Impression Scale severity scores decreased from 5.7 to 3.7 in ALGO compared to only 5.8 to 4.8 in the control (p <.003).
CONCLUSIONS: There was clear improvement in clinical symptoms, functioning, and global response with ALGO treatment. The magnitude of the improvement was greater in children and adolescents treated with the ALGO program compared with a historical cohort. These data support the need for controlled studies in larger populations examining the effects of algorithm-driven disease management programs on the clinical outcomes of children with mental illness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100558     DOI: 10.1097/00004583-200405000-00005

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  6 in total

Review 1.  Psychopharmacologic treatment of pediatric major depressive disorder.

Authors:  Khrista Boylan; Soledad Romero; Boris Birmaher
Journal:  Psychopharmacology (Berl)       Date:  2006-08-08       Impact factor: 4.530

2.  A psychoeducational program for children with ADHD or depression and their families: results from the CMAP feasibility study.

Authors:  Molly A Lopez; Marcia G Toprac; M Lynn Crismon; Christine Boemer; Jennifer Baumgartner
Journal:  Community Ment Health J       Date:  2005-02

Review 3.  A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment.

Authors:  W Burleson Daviss
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-12       Impact factor: 2.576

4.  Concurrent treatment for adolescent and parent depressed mood and suicidality: feasibility, acceptability, and preliminary findings.

Authors:  Anthony Spirito; Jennifer C Wolff; Lourah M Seaboyer; Jeffrey Hunt; Christianne Esposito-Smythers; Nicole Nugent; Caron Zlotnick; Ivan Miller
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-14       Impact factor: 2.576

5.  Effectiveness of an Integrated Care Pathway for Adolescents with Depression: A Pilot Clinical Trial Protocol.

Authors:  Darren B Courtney; Amy Cheung; Joanna Henderson; Kathryn Bennett; Marco Battaglia; John Strauss; Rachel Mitchell; Karen Wang; Peter Szatmari
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2019-11-01

Review 6.  A systematic review of mental health outcome measures for young people aged 12 to 25 years.

Authors:  Benjamin Kwan; Debra J Rickwood
Journal:  BMC Psychiatry       Date:  2015-11-14       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.